Pediatric pulmonology | 20 Apr 2018
K Uda, Y Okubo, K Shoji, I Miyairi, N Morisaki, N Michihata, H Matsui, K Fushimi and H Yasunaga
Neuraminidase inhibitors are recommended for children hospitalized with influenza-related respiratory infections, and oseltamivir is the first choice of treatment in most situations. However, little is known regarding the recent trend in using neuraminidase inhibitors and their difference in health economy. The aim of this study was to reveal recent trends in neuraminidase inhibitor use and compare hospitalization costs across different treatment regimens.
* Data courtesy of Altmetric.com